恩替卡韦联合复方鳖甲软肝片治疗HBeAg阳性失代偿期肝硬化患者的疗效分析

doi:10.3760/cma.j.issn.1007-1245.2023.10.016

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (10): 1404-1408.DOI: 10.3760/cma.j.issn.1007-1245.2023.10.016

恩替卡韦联合复方鳖甲软肝片治疗HBeAg阳性失代偿期肝硬化患者的疗效分析

田昊¹ 宫雪莲¹ 丁坤²

¹烟台市奇山医院药剂科，烟台　264000；²烟台市奇山医院肝病二科，烟台　264000

收稿日期:2022-12-23 出版日期:2023-05-15 发布日期:2023-05-16
通讯作者: 丁坤，Email：ding031606@aliyun.com
基金资助:
山东省医药卫生科技发展计划项目（2017WS239）

Therapeutic effect of entecavir combined with Fufang Biejia Ruangan tablets for patients with HBeAg-positive decompensated cirrhosis

Tian Hao¹, Gong Xuelian¹, Ding Kun²

¹Department of Pharmacy, Yantai Qishan Hospital, Yantai 264000, China; ²Second Department of Liver Diseases, Yantai Qishan Hospital, Yantai 264000, China

Received:2022-12-23 Online:2023-05-15 Published:2023-05-16
Contact: Ding Kun, Email: ding031606@aliyun.com
Supported by:
Project of Plan of Medical and Health Science and Technology Development in Shandong (2017WS239)

摘要/Abstract

摘要：

目的　探讨恩替卡韦联合复方鳖甲软肝片治疗HBeAg阳性失代偿期肝硬化患者的临床疗效。方法　前瞻性选取2017年9月至2021年9月于烟台市奇山医院收治的100例HBeAg阳性失代偿期肝硬化患者为研究对象，随机数字表法分为观察组、对照组，各50例。对照组男30例，女20例，年龄（43.29±5.02）岁，给予恩替卡韦治疗；观察组男26例，女24例，年龄为（40.16±6.25）岁，给予恩替卡韦联合复方鳖甲软肝片治疗。对比两组患者治疗疗效及治疗前后的肝功能指标［丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、白蛋白（ALB）、总胆红素（TBIL）］、肝纤维化程度指标［层黏蛋白（LN）、Ⅲ型前胶原（PCⅢ）、Ⅳ型胶原（CⅣ）、透明质酸（HA）］、门静脉内径及脾厚度评分变化水平以及用药安全性。计量资料采用t检验，计数资料用χ²检验。结果　观察组临床总有效率为92.00%（46/50），高于对照组［70.00%（35/50）］（χ²=7.862，P=0.005）。治疗后，观察组ALT（90.35±35.52）U/L、AST（62.27±30.28）U/L、TBIL（35.09±15.23）μmol/L，均低于对照组［（127.96±48.32）U/L、AST（100.91±42.21）U/L、TBIL（51.15±20.57）μmol/L］（t=4.435、5.259、4.437，均P<0.05）；观察组ALB（34.98±8.34）g/L，高于对照组［（28.33±6.35）g/L］（t=4.486，P<0.05）。治疗后，观察组LN（103.25±32.52）μg/L、PCⅢ（96.17±30.28）μg/L、CⅣ（56.12±26.19）μg/L、HA（155.42±72.71）μg/L，均低于对照组［（129.36±60.33）μg/L、（120.08±52.16）μg/L、（78.33±30.22）μg/L、（194.34±100.29）μg/L］（t=2.694、2.803、3.927、2.222，均P<0.05）。治疗后，观察组门静脉内径（1.03±0.18）cm、脾厚度（3.27±0.39）cm，均明显低于对照组［（1.35±0.27）cm、（4.33±0.31）cm］（t=6.973、15.045，均P<0.05）。两组不良反应发生率比较，差异无统计学意义。结论　恩替卡韦联合复方鳖甲软肝片治疗HBeAg阳性失代偿性肝硬化患者的临床疗效显著，能改善肝纤维化，控制病情发展，同时用药具有较高安全性，不会明显增加不良反应。

关键词:

恩替卡韦, 复方鳖甲软肝片, HBeAg阳性, 失代偿性肝硬化

Abstract:

Objective　To investigate the clinical efficacy of entecavir combined with Fufang Biejia Ruangan tablets in the treatment of patients with HBeAg-positive decompensated cirrhosis. Methods　One hundred patients with HBeAg-positive decompensated cirrhosis admitted to Yantai Qishan Hospital from September 2017 to September 2021 were prospectively selected as the study objects, and were randomly divided into an observation group and a control group, with 50 cases in each group. There were 30 males and 20 females in the control group; they were (43.29±5.02) years old. There were 26 males and 24 females in the control group; they were (40.16±6.25) years old. The control group were treated with entecavir, and the observation group with entecavir and Fufang Biejia Ruangan tablets. The therapeutic efficacies, liver function indicators, such as alanine aminotransferase (ALT), aspartate transferase (AST), albumin (ALB), and total bilirubin (TBiL), and liver fibrosis indicators, such as laminin (LN), procollagen type Ⅲ (PC Ⅲ), collagen type Ⅳ (CⅣ), and hyaluronic acid (HA) before and after the treatment were compared between the two groups. The changes in portal vein diameter and spleen thickness scores, as well as drug safety were also compared. t test was used for the measurement data, and χ² test for the counting data. Results　The total clinical efficacy in the observation group was higher than that in the control group [92.00% (46/50) vs. 70.00% (35/50); χ²=7.862, P=0.005]. After the treatment, the levels of ALT, AST, and TBiL in the observation group were significantly lower than those in the control group [(90.35±35.52) U/L vs. (127.96±48.32) U/L, (62.27±30.28) U/L vs. (100.91±42.21) U/L, and (35.09±15.23) μmol/L vs. (51.15±20.57) μmol/L; t=4.435, 5.259, and 4.437; all P<0.05]; the ALB level in the observation group was significantly higher than that in the control group [(34.98±8.34) g/L vs. (28.33±6.35) g/L; t=4.486, P<0.05]. After the treatment, the levels of LN, PCⅢ, CⅣ, and HA in the observation group were significantly lower than those in the control group [(103.25±32.52) μg/L vs. (129.36±60.33) μg/L, (96.17±30.28) μg/L vs. (120.08±52.16) μg/L, (56.12±26.19) µg/L vs. (78.33±30.22) μg/L, and (155.42±72.71) μg/L vs. (194.34±100.29) μg/L; t=2.694, 2.803, 3.927, and 2.222; all P<0.05]. After the treatment, the portal vein diameter and spleen thickness of the observation group were significantly lower than those of the control group [(1.03±0.18) cm vs. (1.35±0.27) cm and (3.27±0.39) vs. (4.33±0.31); t=6.973 and 15.045, both P<0.05]. There was no statistical difference in the incidence of adverse reactions between the two groups. Conclusions　Entecavir combined with Fufang Biejia Ruangan tablets in the treatment of patients with HBeAg-positive decompensated cirrhosis is significantly effective, an can improve their liver fibrosis and control the disease progress. At the same time, the medication has a high safety profile and does not significantly increase adverse reactions.

Key words:

Entecavir, Fufang Biejia Ruangan tablets, HBeAg-positive, Decompensated cirrhosis

田昊宫雪莲丁坤.

恩替卡韦联合复方鳖甲软肝片治疗HBeAg阳性失代偿期肝硬化患者的疗效分析 [J]. 国际医药卫生导报, 2023, 29(10): 1404-1408.

Tian Hao, Gong Xuelian, Ding Kun.

Therapeutic effect of entecavir combined with Fufang Biejia Ruangan tablets for patients with HBeAg-positive decompensated cirrhosis [J]. International Medicine and Health Guidance News, 2023, 29(10): 1404-1408.

参考文献

[1] 袁媛,陈洁,杨雪梅,等.国产恩替卡韦对HBeAg阳性代偿期乙肝肝硬化患者HBV复制的抑制效果、血清球蛋白及补体C3、C4的影响研究[J].川北医学院学报,2020,35(3):432-435,449.DOI:10.3969/j.issn.1005-3697.2020.03.019.
[2] 庞文艳,杨宏伟,齐宁,等.前列地尔联合复方鳖甲软肝片和恩替卡韦治疗HBeAg阳性的乙肝失代偿期肝硬化患者的临床效果[J].中国医药导报,2020,17(36):130-134.
[3] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].中华传染病杂志,2019,37(12):711-736.DOI:10.3760/cma.j.issn.1000-6680. 2019.12.003.
[4] 孔媛媛,魏巍,单姗,等.乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J].肝脏,2020,25(2):123-127.DOI:10.3969/j.issn.1008-1704.2020.02.012.
[5] Tandon P, Montano-Loza AJ, Lai JC, et al. Sarcopenia and frailty in decompensated cirrhosis[J]. J Hepatol, 2021,75 Suppl 1:S147-S162. DOI: 10.1016/j.jhep.2021.01.025.
[6] Shi M, Li YY, Xu RN, et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial[J]. Hepatol Int, 2021,15(6):1431-1441. DOI: 10.1007/s12072-021-10199-2.
[7] Roberts D, Best LM, Freeman SC, et al. Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021,4(4):CD013155. DOI: 10.1002/14651858.CD013155.pub2.
[8] Okubo T, Atsukawa M, Tsubota A, et al. Effect of vitamin d supplementation on skeletal muscle volume and strength in patients with decompensated liver cirrhosis undergoing branched chain amino acids supplementation: a prospective, randomized, controlled pilot trial[J]. Nutrients, 2021,13(6):1874. DOI: 10.3390/nu13061874.
[9] An J, Park DA, Ko MJ, et al. Direct-acting antivirals for HCV Treatment in decompensated liver cirrhosis patients: a systematic review and meta-analysis[J]. J Pers Med, 2022,12(9):1517. DOI: 10.3390/jpm12091517.
[10] Zhu Z, Liu Y, Wu W, et al. Liver transplantation reverses hepatic myelopathy in hepatitis b-related decompensated liver cirrhosis: case report and review of the literature[J]. Transplant Proc, 2022,54(1):158-160. DOI: 10.1016/j.transproceed.2021.11.016.
[11] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022,77(6):1564-1572. DOI: 10.1016/j.jhep.2022.07.037.
[12] Chen CH, Chen CY, Wang JH, et al. Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study[J]. Am J Cancer Res, 2020,10(11):3882-3895.
[13] 李念,李媛,赵凯杰,等.调肝化纤丸联合恩替卡韦治疗乙肝肝硬化代偿期疗效分析[J].天津中医药大学学报,2020,39(2):169-172.DOI:10.11656/j.issn.1673-9043. 2020.02.11.
[14] 石俊,袁芳,朱琳,等.叶天士活血通络消胀方联合恩替卡韦治疗失代偿期乙型肝炎肝硬化92例[J].中西医结合肝病杂志,2020,30(4):360-362.DOI:10.3969/j.issn.1005-0264. 2020.04.022.
[15] 武淑芳,赵夏平,张健,等.恩替卡韦联合复方鳖甲软肝片对乙型肝炎肝硬化代偿期活动期患者血清肝纤维化及乙型肝炎病毒相关指标的影响[J].中国药物与临床,2022,22(3):269-272.DOI:10.11655/zgywylc2022.03.021.
[16] 冯志刚,李涛,赵冰清,等.复方鳖甲软肝片联合恩替卡韦对乙肝肝硬化失代偿期患者疗效、肝功能、免疫功能影响研究[J].中华中医药学刊,2022,40(1):184-187.DOI:10.13193/j.issn.1673-7717.2022.01.044.
[17] 郑晓永,白艳,张娟.复方鳖甲软肝片联合替诺福韦酯治疗慢性乙型肝炎肝硬化的临床研究[J].现代药物与临床,2022,37(4):786-790.DOI:10.7501/j.issn.1674-5515. 2022.04.019.
[18] 朱海洋,高红伟,韩仙芝,等.恩替卡韦联合复方鳖甲软肝片治疗不同时期慢性乙型肝炎肝硬化疗效及其与趋化因子受体的关系[J].中西医结合肝病杂志,2021,31(5):405-408.DOI:10.3969/j.issn.1005-0264.2021.05.006.

恩替卡韦联合复方鳖甲软肝片治疗HBeAg阳性失代偿期肝硬化患者的疗效分析

Therapeutic effect of entecavir combined with Fufang Biejia Ruangan tablets for patients with HBeAg-positive decompensated cirrhosis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics